Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBX 12

Next Previous
Drug Profile

CBX 12

Alternative Names: alphalex™-exatecan; CBX-12

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cybrexa Therapeutics
  • Developer Cybrexa Therapeutics; National Cancer Institute (USA)
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Peptide drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Ovarian cancer
  • Preclinical Cancer

Most Recent Events

  • 03 Jun 2025 Phase-II clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06730100)
  • 12 Dec 2024 Cybrexa Therapeutics in collaboration with the National Cancer Institute plans a II trial for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater), in May 2025 (NCT06730100)
  • 07 Oct 2024 Cybrexa Therapeutics plans a phase II trial in Solid tumours(Combination therapy, Monotherapy) in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top